Phase 1 Study of Vorinostat as a Radiation Sensitizer with (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

PURPOSE: (131)I-metaiodobenzylguanidine (MIBG) is a radiopharmaceutical with activity in neuroblastoma. Vorinostat is a histone deacetylase inhibitor that has radiosensitizing properties. The goal of this phase 1 study was to determine the maximum tolerated doses of vorinostat and MIBG in combinatio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: DuBois, Steven G., Groshen, Susan, Park, Julie R., Haas-Kogan, Daphne A., Yang, Xiaodong, Geier, Ethan, Chen, Eugene, Giacomini, Kathy, Weiss, Brian, Cohn, Susan L., Granger, M. Meaghan, Yanik, Gregory A., Hawkins, Randall, Courtier, Jesse, Jackson, Hollie, Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Tsao-Wei, Denice, Villablanca, Judith G., Marachelian, Araz, Matthay, Katherine K.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4470833/
https://ncbi.nlm.nih.gov/pubmed/25695691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3240
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars